Abacus Medicine Pharma Services (AMPS) and Gen.Orph are proud to announce the signing of a partnership agreement for the exclusive marketing and distribution of Miglustat Gen.Orph in Austria.
Miglustat Gen.Orph 100 mg hard capsules is indicated for the oral treatment of mild to moderate type 1 Gaucher disease in adult patients. It must only be used to treat patients for whom enzyme replacement therapy is not an option. In addition, Miglustat Gen.Orph is indicated for the treatment of progressive neurological manifestations in adult and pediatric patients with Niemann-Pick type C disease.
Miglustat Gen.Orph has obtained reimbursement for both indications and is positioned in the yellow-box according to the Erstattungskodex (list of reimbursed pharmaceutical products).
Simon Estcourt, Managing Director of Abacus Medicine Pharma Services explains, “This is an exciting opportunity for both companies as it unlocks new geographies for Gen.Orph making the alternative treatment option available to patients and prescribers.”
Etienne Jacob, CEO and Founder of Gen.Orph continues, “Due to the low prevalence of lysosomal disorders, the launch of Miglustat Gen.Orph in Austria was unlikely to happen. However, working in partnership with Abacus Medicine Pharma Services, their innovative approach has enabled us to respond to the market needs of patients and prescribers by delivering choice via the first dual-indication Miglustat therapy into the Austrian market.”
Product information:
- Miglustat Gen.Orph 100mg hard capsules 84 pieces
- PhZNr 5512466
- Distribution is via the full range of pharmaceutical wholesalers